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Core evidence place in therapy summary for sevelamer as a phosphate binder in adult hemodialysis patients

  **Outcome measure**                                                                                                          **Evidence**                                                            **Implications**
  ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  **Disease-oriented evidence**                                                                                                                                                                        
  Effective control of serum phosphate and Ca × P product to within K/DOQI target range                                        Clear                                                                   Sevelamer is as effective as calcium salts
  Absence of hypercalcemia                                                                                                     Clear                                                                   Reduced incidence of hypercalcemia with sevelamer compared with calcium salts
  Reduction in serum LDL cholesterol and total cholesterol                                                                     Clear                                                                   Sevelamer is more effective than calcium salts
                                                                                                                               May have beneficial effects on cardiovascular morbidity and mortality   
  Reduction in vascular calcification                                                                                          Substantial                                                             Attenuated progression with sevelamer compared with calcium salts
                                                                                                                               May have beneficial effects on cardiovascular morbidity and mortality   
  Reduction in serum uric acid concentration                                                                                   Moderate                                                                Greater reduction with sevelamer than with calcium salts
  Metabolic acidosis                                                                                                           Moderate                                                                Sevelamer may be more likely than calcium salts to induce metabolic acidosis
  Preservation of trabecular bone mineral density                                                                              Limited                                                                 Better preservation with sevelamer than with calcium salts
                                                                                                                               May improve morbidity due to bone disease                               
  **Patient-oriented evidence**                                                                                                                                                                        
  Improvement in cardiovascular morbidity and mortality                                                                        Limited                                                                 Reduced risk of cardiac mortality and morbidity with sevelamer compared with calcium salts
  Reduction in hospitalization                                                                                                 Limited                                                                 Lower risk with sevelamer than with calcium salts
  Absence of gastrointestinal adverse events                                                                                   Limited                                                                 Evidence divided on whether the incidence with sevelamer is similar to or higher than with calcium salts
  Improved patient acceptability (e.g. reduction of the dose required leading to a lower phosphate binder medication burden)   Limited                                                                 No improvement over calcium salts
  Improvement of ulcers due to calcific uremic arteriolopathy                                                                  Limited                                                                 Improvement and/or healing noted after switching to sevelamer in combination with other interventions
  Improvement in quality of life                                                                                               No evidence                                                             
  **Economic evidence**                                                                                                                                                                                
  Cost-effectiveness as a phosphate binder in hemodialysis patients                                                            Limited                                                                 \$US1100--2200 per life-year gained with sevelamer compared with calcium salts
  Cost-effectiveness as a lipid-lowering therapy in predialysis patients                                                       Limited                                                                 Less cost-effective than atorvastatin (specific lipid-lowering therapy) plus calcium salts

Scope, aims, and objectives
===========================

Sevelamer (Renagel^®^, Genzyme) is indicated for the treatment of hyperphosphatemia in adult patients undergoing hemodialysis for end-stage renal failure. Sevelamer reduces serum phosphate concentrations by binding phosphate ions in the gastrointestinal tract, thus preventing systemic absorption. It differs from other currently available phosphate binders in that it is not a metal salt but a crosslinked polymer containing multiple amine groups. Sevelamer is administered in the hydrochloride form with hydrochloride groups bound to the amine groups. In the gastrointestinal tract, the amine groups become protonated and positively charged, and preferentially bind to phosphate ions, displacing some of the hydrochloride. Maximum phosphate binding occurs at about pH 7, and sevelamer binds phosphate mainly in the duodenum ([@b3-ce-1-043]). Studies in animals and in healthy volunteers have shown that the sevelamer polymer is not absorbed from the gut, and that both the polymer and the bound phosphate are excreted in the feces ([@b13-ce-1-043]; [@b63-ce-1-043]). Sevelamer contains no metal ion component that could result in potential metal toxicity. The only component of sevelamer that is absorbed is some of the hydrochloride, which could contribute to metabolic acidosis ([@b48-ce-1-043]).

This article reviews the evidence for the use of sevelamer as a phosphate binder in adult patients on hemodialysis, and considers its effects on outcomes, including serum phosphate and calcium concentrations, arterial calcification, hospitalization, and cardiovascular morbidity and mortality.

Use in children and in patients not undergoing hemodialysis (e.g. peritoneal dialysis patients or patients not on dialysis) is excluded, as these indications are not presently approved.

Methods
=======

Literature searches were conducted on January 9--21, 2005, in the following databases. The search strategy was "Renagel OR sevelamer" unless otherwise stated. The cut-off date was from the beginning of the database to the date of the search unless otherwise stated.

-   PubMed, <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>, 1966 to date. Search strategy: "sevelamer AND (hemodialysis OR haemodialysis)" limited to English-language results only, which was expanded by Automatic Term Mapping to "('sevelamer'\[Substance Name\] OR sevelamer\[Text Word\]) AND ((hemodialysis\[Text Word\] OR haemodialysis\[Text Word\] OR ('renal dialysis'\[TIAB\] NOT Medline\[SB\]) OR 'renal dialysis'\[MeSH Terms\]) OR (hemodialysis\[Text Word\] OR haemodialysis\[Text Word\] OR ('renal dialysis'\[TIAB\] NOT Medline\[SB\]) OR 'renal dialysis'\[MeSH Terms\])) AND English\[Lang\]"

-   EMBASE, <http://www.datastarweb.com>, 1974 to date. Search strategy: "sevelamer AND (hemodialysis OR haemodialysis)" limited to English-language results only

-   Database of Abstracts of Reviews of Effectiveness (DARE), NHS Economic Evaluations Database (NHSEED), Health Technology Assessment (HTA), [www.york.ac.uk/inst/crd/darehp.htm](www.york.ac.uk/inst/crd/darehp.htm). All three databases were searched together. All fields searched

-   NHS HTA, [www.ncchta.org](www.ncchta.org)

-   National Guideline Clearing House, [www.guideline.gov](www.guideline.gov)

-   National Institute for Health and Clinical Excellence (NICE), [www.nice.org.uk](www.nice.org.uk)

-   Cochrane Database of Systematic Reviews (CDSR), [www.cochrane.org/index0.htm](www.cochrane.org/index0.htm). Entire site searched

-   Clinical Evidence (BMJ), [www.clinicalevidence.com](www.clinicalevidence.com)

One set of clinical guidelines was identified from the National Guidelines Clearing House ([@b60-ce-1-043]). After removal of duplicates, a total of 142 records were retrieved, two from DARE and the remainder from PubMed or EMBASE. All other databases recorded no matches. Records were manually reviewed and a total of 114 records were excluded: nonsystematic reviews (n=49), animal studies (n=3), *in vitro* studies (n=1), studies in children (n=3), studies in patients other than hemodialysis patients (n=4), letters, editorials, comment and corrections (n=25), and articles that mentioned sevelamer but did not investigate its clinical use (n=29). The remaining 28 records were included in the review. Review of the reference lists of the systematic review and the meta analysis identified two further papers for inclusion. An additional study, submitted to a meeting in 2000 but otherwise apparently unpublished, was identified in a review article and also included, bringing the total to 31 ([Table 1](#t1-ce-1-043){ref-type="table"}).

Meeting abstracts from 2002 to date were identified by searching BIOSIS Previews, <http://www.datastarweb.com>, 1996 to date, using the search strategy "sevelamer AND (hemodialysis OR haemodialysis) AND LG=EN AND PT=MEETING\$ AND (YEAR=2002 OR YEAR=2003 OR YEAR=2004 OR YEAR=2005)" on February 16, 2005. A total of 21 records were retrieved, of which nine were excluded because they were animal studies (n=1), studies that did not investigate the clinical use of sevelamer (n=3), or duplicate publications of data presented in full papers (n=5). The remaining 12 were included in the review. In addition, abstracts from the American Society of Nephrology (ASN) Annual Meeting 2004 were searched on January 20, 2005 ([www.abstracts2view.com](www.abstracts2view.com)), using the search terms "(sevelamer OR Renagel) AND hemodialysis." This yielded 14 records, of which 10 were excluded because they were animal studies (n=3) or did not investigate the clinical use of sevelamer in hemodialysis patients (n=7), leaving four abstracts for inclusion in the review ([Table 1](#t1-ce-1-043){ref-type="table"}).

The searches were updated on April 29, 2005. After excluding duplicates, a total of 23 new records were identified, of which 17 were excluded for the following reasons: nonsystematic reviews (n=6), letters (n=3), and articles that mentioned sevelamer but did not investigate its clinical use (n=8). Six articles remained, all full papers, and were included ([Table 1](#t1-ce-1-043){ref-type="table"}).

For each outcome, preference was given to level 1 and 2 evidence (see Editorial Information on inside back cover). Level 3 evidence was also included where level 1 and 2 evidence was lacking or conflicting. Outcomes from original level 2 or 3 studies, covered in level 1 evidence, were not considered separately in this review. As a result, five level 3 papers ([@b37-ce-1-043]; [@b87-ce-1-043]; [@b6-ce-1-043]; [@b19-ce-1-043]; [@b75-ce-1-043]) and four level 3 abstracts ([@b54-ce-1-043]; [@b58-ce-1-043]; [@b78-ce-1-043]; [@b88-ce-1-043]) which presented data only on outcomes for which substantial level 1 and 2 evidence was identified are not considered in this review. Two level 2 papers presented only outcomes data that were already included in level 1 evidence and are not discussed separately ([@b17-ce-1-043]; [@b18-ce-1-043]).

Disease overview
================

Chronic kidney disease
----------------------

Chronic kidney disease (CKD) is classified by the National Kidney Foundation (NKF) guidelines into five stages of severity, defined according to the glomerular filtration rate (GFR) ([@b60-ce-1-043]). Stage 5, kidney failure, is also known as end-stage renal disease (ESRD) or established renal failure (ERF), and requires renal replacement therapy (RRT; regular dialysis or a kidney transplant) if the patient is to survive ([@b61-ce-1-043]). Dialysis must be repeated at regular intervals for the rest of the patient's life or until a successful kidney transplant is performed. The major forms of dialysis are hemodialysis and peritoneal dialysis, though only hemodialysis is considered in this review. CKD is a priority area for the UK National Health Service (NHS), and standards of care are recommended in the National Service Framework for renal services ([@b61-ce-1-043]). These recommend that CKD management should begin before dialysis is required, as this improves outcomes. Treatment should include correction of anemia, improvement of nutrition, preventing the development of renal bone disease, management of comorbid diseases (e.g. cardiovascular disease, diabetes), and helping the patient to choose and prepare for a particular form of RRT ([@b61-ce-1-043]).

CKD is a common disorder, which is increasing in prevalence as the average age of populations increases. In England, there were 547 patients per million population undergoing RRT in 2001, up from 396 per million population in 1992 ([@b61-ce-1-043]). In the USA the number of patients on RRT in 2001 was 1403 per million population, and in Europe it varied from 606 (Norway) to 1022 per million population (Catalonia, Spain) ([@b61-ce-1-043]). In England in 2001, patients on RRT were divided approximately equally between those with a functioning transplant and those on dialysis. However, the number on hospital hemodialysis is projected to increase faster than those on other treatments ([@b61-ce-1-043]).

CKD imposes considerable economic and social burdens on the patients, their families, and healthcare providers ([@b61-ce-1-043]). It has been estimated that the treatment of patients undergoing RRT accounts for 1--2% of the total UK NHS annual budget, while hemodialysis is estimated to cost approximately £21 000 per patient per year ([@b61-ce-1-043]). Mortality in CKD patients is higher compared with the general population; in a survey of 5% of US Medicare recipients (over 1 million people), the 2-year risk of death was 17.7 per 100 patient-years for patients with CKD compared with 5.5 per 100 patient-years for those without CKD ([@b34-ce-1-043]). Cardiovascular disease accounts for most of this excess mortality ([@b55-ce-1-043]). Patients with CKD have been shown to have higher risks of congestive heart failure (30.7 vs 8.6 per 100 patient-years) and atherosclerotic vascular disease (35.7 vs 14.1 per 100 patient-years) compared with those without CKD ([@b34-ce-1-043]).

Hyperphosphatemia in CKD
------------------------

Hyperphosphatemia is common in patients with stages 4 and 5 CKD. In healthy adults, phosphate absorbed from the diet is excreted by the kidney, and average daily excretion balances average daily absorption ([@b31-ce-1-043]). This is achieved by large amounts of phosphate being filtered from the blood into the renal tubule. More than 90% of the filtered phosphate is then reabsorbed to maintain phosphate balance. Phosphate reabsorption is regulated by parathyroid hormone (PTH); increased serum PTH reduces phosphate reabsorption in the kidney tubule ([@b60-ce-1-043]). In advanced CKD (stage 4 or 5), when the GFR has fallen to \<30 mL/min per 1.73 m^2^, the kidney can no longer adequately handle phosphate loads and hyperphosphatemia develops ([@b60-ce-1-043]).

The average phosphorus intake of adults in North America and Europe is approximately 1000 mg/day in women and 1500 mg/day in men, of which about 60--70% is absorbed. A typical 4-h hemodialysis session removes approximately 1000 mg of phosphorus ([@b31-ce-1-043]). However, since hemodialysis is normally performed every few days, this is not adequate to remove enough phosphate to restore normal serum phosphate levels ([@b39-ce-1-043]).

Phosphate balance is closely connected with calcium balance and bone metabolism, and numerous interrelated factors influence the level of serum phosphate in patients with CKD ([@b60-ce-1-043]). [Fig. 1](#f1-ce-1-043){ref-type="fig"} illustrates some of the mechanisms involved.

Normal kidneys produce the active form of vitamin D, which increases absorption of calcium and phosphate from the gut. In CKD, levels of active vitamin D drop, producing hypocalcemia, which in turn stimulates release of PTH. PTH increases bone resorption and release of calcium and phosphate from the skeleton, thereby increasing serum calcium and tending to correct the hypocalcemia. In healthy individuals, PTH also increases urinary phosphate excretion by decreasing tubular reabsorption. However, in advanced CKD the kidneys are unable to remove the excess phosphate and hyperphosphatemia results ([@b60-ce-1-043]). High levels of serum phosphate are associated with hyperplasia of the parathyroid glands ([@b76-ce-1-043]) and directly stimulate PTH synthesis and secretion ([@b76-ce-1-043]; [@b60-ce-1-043]), producing a positive feedback loop in which elevated PTH and serum phosphate levels increase each other and move the system further from normal values. Some medical interventions intended to correct aspects of bone and mineral metabolism in CKD may also contribute to hyperphosphatemia. For example, administration of calcitriol (an active form of vitamin D) to patients with CKD may help to correct hypocalcemia and reduce the excess secretion of PTH, but may also aggravate hyperphosphatemia by increasing intestinal absorption of phosphate ([@b60-ce-1-043]).

Consequences of hyperphosphatemia
---------------------------------

Hyperphosphatemia, via its effects on PTH, is established as one of the causes of osteitis fibrosa in CKD patients ([@b28-ce-1-043]; [@b60-ce-1-043]). Osteitis fibrosa is characterized by high serum PTH, high resorption and high turnover of bone, and may produce skeletal softening and/or deformation. The high bone turnover releases skeletal phosphate and calcium and may further increase serum phosphate levels (see above). The pathogenesis of the other main form of bone disease in patients with CKD, adynamic bone disease, is not fully understood, but is thought to be related to oversuppression of PTH by high calcium intake and/or administration of calcitriol ([@b60-ce-1-043]). Adynamic bone disease is characterized by an unusually low turnover of bone and occurs in 15--60% of dialysis patients ([@b60-ce-1-043]). This low bone turnover means that calcium and phosphate are not absorbed into bone and accumulate in the blood. Adynamic bone disease can thus contribute to hyperphosphatemia and hypercalcemia.

In a study of 202 patients followed for a mean of 45 months after beginning RRT, a serum phosphate level \>1.85 mmol/L after 1 year of dialysis was associated with a 2.63 times higher risk of requiring surgical removal of the parathyroid glands (parathyroidectomy) than in those with a serum phosphate level ≤1.85 mmol/L (*P*=0.006) ([@b43-ce-1-043]). The association between elevated serum phosphate and risk of parathyroidectomy was independent of PTH level, and the authors considered it was likely to be causal ([@b43-ce-1-043]).

Elevated serum phosphate has been shown to be a risk factor for increased mortality in hemodialysis patients ([@b7-ce-1-043], [@b8-ce-1-043]), and this mortality risk was independent of PTH ([@b7-ce-1-043]). A similar risk was observed if the serum calcium--phosphate product (Ca × P; the calcium concentration in mg/dL multiplied by the phosphate concentration in mg/dL) exceeded 72 mg^2^/dL^2^ ([@b7-ce-1-043]). The Dialysis Outcomes and Practice Patterns Study (DOPPS), conducted in over 6000 dialysis patients from seven countries, also observed that high serum phosphate and Ca × P were associated with significantly (*P*\<0.0001) increased cardiovascular and all-cause mortality ([@b89-ce-1-043]). High serum calcium was also associated with an increased risk of death in two studies ([@b8-ce-1-043]; [@b89-ce-1-043]) but not in another ([@b7-ce-1-043]). It has been suggested that serum phosphate may be the major determinant of Ca × P product ([@b43-ce-1-043]).

Hyperphosphatemia and elevated Ca × P product are associated with soft-tissue calcification, in which calcium phosphate minerals are laid down in soft tissues, such as the blood vessels (vascular calcification), eyes (ocular calcification), visceral organs (visceral calcification), skin (cutaneous calcification), and around the joints (periarticular calcification) ([@b28-ce-1-043]; [@b60-ce-1-043]). Soft-tissue calcification is most common when Ca × P exceeds 70mg^2^/dL^2^ ([@b60-ce-1-043]), and is a major mortality and morbidity risk factor in CKD patients ([@b60-ce-1-043]). It can occur in patients with elevated PTH and in patients with normal PTH and adynamic bone disease ([@b28-ce-1-043]).

Soft-tissue calcification in CKD---effects on morbidity and mortality
---------------------------------------------------------------------

The most serious clinical consequences of soft-tissue calcification are due to visceral or vascular calcification, and may be one mechanism underlying the excess mortality risk with high serum phosphate and/or Ca × P observed in hemodialysis patients ([@b71-ce-1-043]; [@b60-ce-1-043]). It should be noted that calcium overload can also occur without hypercalcemia, as can the clinical consequences (e.g. in uremic patients where transfer to the skeletal buffer is the only route available to "eliminate" excess ingested calcium). Visceral calcification of the heart muscle, valves, and/or cardiac conduction system may result in congestive heart failure, cardiac arrhythmias, and heart block, while calcium deposition in the lungs may produce pulmonary fibrosis, pulmonary hypertension, and right ventricular hypertrophy ([@b60-ce-1-043]).

The prevalence of vascular calcification increases with the length of time a patient has been on dialysis; prevalence has been reported as 27% in patients on dialysis for less than 1 year compared with 83% in those on dialysis for more than 8 years ([@b60-ce-1-043]). It can involve any artery and shows little tendency to regress. There are two main forms of vascular calcification ([@b60-ce-1-043]); arteriosclerosis (medial calcification), in which calcium deposits are laid down in the artery wall stiffening it and reducing elastic arterial compliance, and atherosclerosis (intimal calcification), in which calcium deposits are laid down in plaques on the inner surface of the arterial wall which partially occlude the lumen and restrict blood flow. Both forms of arterial calcification have been associated with disturbances of calcium and phosphate balance ([@b30-ce-1-043]), and both can cause cardiovascular complications. Reduction in elastic arterial compliance increases the strain on the heart and contributes to the development of left ventricular hypertrophy ([@b46-ce-1-043]). In a cohort of 202 hemodialysis patients, individuals with either intimal or medial arterial calcification had a significantly (*P*\<0.01) higher all-cause mortality than patients without calcification ([@b49-ce-1-043]). A further study in 110 hemodialysis patients found that arterial calcification score (assessed by the presence of calcified plaques detected by ultrasonography and/or calcification visible on soft-tissue radiographs) and arterial elasticity, were the only risk factors independently associated with all-cause and cardiovascular mortality over a mean of 53 months of follow-up ([@b5-ce-1-043]).

The causes of arterial calcification are not fully understood. It appears to be an active process in which vascular smooth muscle cells actively take up phosphate and begin to express osteoblast markers (osteoblasts are bone-forming cells) ([@b33-ce-1-043]). Endogenous regulators of calcification, such as fetuin A, osteoprotegerin and matrix Gla protein, may be associated with the pathogenesis of vascular calcification, but their precise role remains to be clarified ([@b45-ce-1-043]; [@b33-ce-1-043]).

Some authorities consider that high doses of calcium salts used as phosphate binders may play an important role, via intestinal absorption of calcium and elevated serum Ca × P product ([@b71-ce-1-043]; [@b29-ce-1-043]). In support of this, a study in 120 hemodialysis patients found that, after adjustment for confounding factors, the prescribed dose of calcium carbonate was one of four variables independently associated with arterial calcification (measured by ultrasonography) ([@b38-ce-1-043]). A further small study in 24 hemodialysis patients found that impaired arterial compliance was associated with duration of hemodialysis and serum total calcium ([@b46-ce-1-043]).

Others have argued that dyslipidemia is an important determinant of vascular calcification ([@b55-ce-1-043]; [@b65-ce-1-043]). A systematic review of 30 studies of coronary vascular calcification in patients with CKD found that the most consistent determinants of calcification were increasing age and duration of dialysis ([@b55-ce-1-043]). Measures of calcium--phosphate balance were found to be associated with calcification in eight studies, while 20 studies found no association ([@b55-ce-1-043]). The authors also reported that serum lipid profile was associated with vascular calcification in four studies, and concluded that dyslipidemia was possibly associated with vascular calcification, whereas calcium--phosphate balance showed inconsistent results and was "likely not related" ([@b55-ce-1-043]). However, it seems that results linking lipid profile to vascular calcification may also be inconsistent, since the authors identified two further studies that found no association between vascular calcification and lipid profile ([@b55-ce-1-043]). In a study of 453 mainly African-American patients on hemodialysis, it was found that 2-year mortality did not correlate with hyperlipidemia ([@b32-ce-1-043]).

There is evidence that the two forms of arterial calcification may differ in their epidemiology. In a cohort of 202 hemodialysis patients, intimal calcification was observed mainly in older patients with typical atherosclerotic risk factors, including dyslipidemia, while medial calcification was observed in young and middle-aged patients and was associated with CKD-specific factors, including longer duration of hemodialysis and high serum phosphate ([@b49-ce-1-043]). Such differences in epidemiology between the two forms may explain the apparent inconsistency of reported associations between vascular calcification and risk factors, but further research is required to clarify this.

A small number of patients with vascular calcification and advanced CKD develop progressive skin ulcerations and tissue necrosis, a syndrome called calciphylaxis or calcific uremic arteriolopathy ([@b47-ce-1-043]; [@b60-ce-1-043]). The mechanism is not well understood, although hyperphosphatemia is an important factor ([@b60-ce-1-043]), and calcium toxicity may also be involved ([@b47-ce-1-043]). The prognosis of patients with calcific uremic arteriolopathy is poor, with most dying of sepsis or ischemic events ([@b47-ce-1-043]).

Metabolic acidosis in CKD
-------------------------

Blood pH, partial pressure of carbon dioxide (CO~2~), and serum bicarbonate concentration are chemically related to one another by a fixed equation, and the key determinant of blood pH is the ratio of dissolved CO~2~ to bicarbonate in the serum. In healthy individuals, the lungs adjust the partial pressure of CO~2~ (which determines the concentration of dissolved CO~2~) and the kidneys adjust the concentration of bicarbonate. A fall in blood pH resulting from an increase in CO~2~ is termed respiratory acidosis, while a fall in blood pH resulting from a fall in serum bicarbonate is termed metabolic acidosis.

Metabolic acidosis in patients with kidney failure may be linked to malnutrition and inflammation ([@b44-ce-1-043]), and it has been suggested that acidosis could be associated with an increased risk of death and increased dissolution of bone ([@b11-ce-1-043]). The NKF Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that predialysis serum levels of total CO~2~ should be maintained at ≥22 mmol/L ([@b60-ce-1-043]). Total CO~2~ is readily measured by automated analyzers and is considered an appropriate proxy for serum bicarbonate ([@b9-ce-1-043]). However, the NKF K/DOQI guidelines consider that acidosis does not play an important role in the pathogenesis of bone disease in CKD ([@b60-ce-1-043]). Furthermore, results from the DOPPS study found that patients with moderate acidosis (predialysis serum total CO~2~ levels of 20.1--22 mmol/L) had lower mortality and hospitalization risks than patients with either severe acidosis (predialysis serum total CO~2~ levels of ≤17 mmol/L) or high predialysis serum total CO~2~ level (\>27 mmol/L) ([@b9-ce-1-043]). There is a lack of evidence for reducing acidosis with bicarbonate supplementation, and its true clinical impact on calcification is unclear.

Current therapy options
=======================

There are three components to a strategy for controlling serum phosphate in ESRD: phosphate removal by dialysis, dietary restriction of phosphate, and use of oral phosphate binders ([@b31-ce-1-043]). The effect of dietary restriction and dialysis is limited because phosphate is abundant in all food groups, and maintaining an adequate protein intake will also result in a phosphate intake that exceeds the amount that can be removed by most forms of dialysis ([@b48-ce-1-043]; [@b31-ce-1-043]). However, there is some recent evidence that quotidian (i.e. short daily dialysis) is more effective than conventional hemodialysis in reducing serum phosphate and the need for phosphate binders ([@b1-ce-1-043]).

Oral phosphate binders are normally required for most patients ([@b31-ce-1-043]). The main currently available phosphate binders are listed in [Table 2](#t2-ce-1-043){ref-type="table"}. Other compounds are used occasionally or are in development (e.g. magnesium salts and iron preparations) ([@b39-ce-1-043]; [@b48-ce-1-043]; [@b31-ce-1-043]).

The occurrence of progressive and sometimes fatal aluminum intoxication in some patients taking aluminum salts has been described as a "medical catastrophe" ([@b39-ce-1-043]), and calcium salts have become the most widely used class of phosphate binder ([@b71-ce-1-043]). [Table 3](#t3-ce-1-043){ref-type="table"} shows the usage of phosphate binders reported in various surveys. Lanthanum carbonate has only recently been approved (October 2004 in the USA) and did not feature in the surveys.

Unmet needs
-----------

Significant problems remain with calcium salts. Large doses are required, especially with calcium carbonate. Calcium carbonate binds phosphate poorly at neutral pH and may have lower effectiveness in patients with impaired gastric acid secretion ([@b48-ce-1-043]). Calcium acetate has about twice the phosphate-binding capacity of calcium carbonate, expressed per milligram of elemental calcium, and can be given at a somewhat lower dose. However, it can cause gastrointestinal adverse effects ([@b48-ce-1-043]). As discussed in the previous section, calcium salts have been associated with an increased incidence of arterial calcification, which has been associated with elevated cardiovascular mortality, although the nature of the relationship is not known ([@b31-ce-1-043]). The lower dose of elemental calcium required with calcium acetate compared with calcium carbonate should theoretically reduce the amount of calcium absorbed and hence the risk of hypercalcemia, but a subanalysis of a randomized controlled trial (RCT) found that changes in arterial calcification (as measured by electron beam tomography) in patients receiving calcium acetate were similar to those in patients receiving calcium carbonate ([@b22-ce-1-043]).

Lanthanum carbonate has only recently become available (FDA approval October 2004). It has the potential to reduce the dosage somewhat compared with calcium salts; median dose required for phosphate control reported as 2.25 g/day for lanthanum carbonate compared with 3 g/day for calcium carbonate ([@b48-ce-1-043]). However, small amounts of lanthanum are absorbed and concerns remain that chronic exposure may lead to lanthanum accumulation and potential toxicity ([@b39-ce-1-043]; [@b31-ce-1-043]). Long-term safety data are needed to address these concerns ([@b39-ce-1-043]; [@b48-ce-1-043]).

Compliance with treatment guidelines
------------------------------------

The NKF K/DOQI treatment guidelines set out targets for various components of calcium--phosphate balance ([Table 4](#t4-ce-1-043){ref-type="table"}).

Several surveys have shown that few patients successfully attain these targets. In a survey of 188 dialysis patients in the USA, only 11 (5.9%) were within the recommended ranges for all five parameters ([@b83-ce-1-043]). In another survey among 1312 patients on hemodialysis at seven centers in Spain, only 13% met K/DOQI targets for Ca × P, serum phosphate, and PTH ([@b51-ce-1-043]). While more than half the patients surveyed in the DOPPS study were outside the target ranges for serum calcium, serum phosphate, and PTH across all seven countries, there was a trend towards improvement between the first DOPPS survey in 1996--2001 and the second in 2002--2004 ([@b89-ce-1-043]). In a small survey in 69 hemodialysis patients at a single center in the Czech Republic (not included in DOPPS), only 20% of patients met all the targets ([@b77-ce-1-043]). The low level of compliance with the NKF K/DOQI guidelines thus indicates that substantial unmet needs still remain in the control of hyperphosphatemia in hemodialysis patients.

One problem is that patient adherence to phosphate binder therapy is poor ([@b39-ce-1-043]); in a survey of 188 US dialysis patients, 37.8% of patients admitted noncompliance (compliance defined as at least 80% of phosphate binders taken correctly) ([@b83-ce-1-043]). The main reasons given for noncompliance were being unaware of the correct prescription (37% of noncompliant patients) and forgetting the dose (30%). However, the burdensome nature of the large doses was also mentioned by some patients: 6% said there were too many pills, 8% said they missed a dose because they were eating out, and 4% said the binder doses were too big to carry ([@b83-ce-1-043]).

Although current phosphate binders may be effective, they have limitations and adverse effects that may compromise optimal treatment. Alternative agents with improved therapeutic value should retain or improve on the effectiveness of current treatments while avoiding or reducing their limitations. The attributes of an ideal phosphate binder include effective control of serum phosphate and Ca × P product to within K/DOQI target range; avoidance of hypercalcemia; absence of metal absorption that may lead to toxicity; absence of troublesome adverse events; improved patient acceptability (e.g. reduction of the dose required leading to a lower tablet burden) and/or improved patient adherence; wide dose range and flexible dosing to accommodate individual differences in dietary phosphate intake; reduction in the risk of soft-tissue and especially vascular calcification; improvement in the morbidity due to bone disease; improvement in cardiovascular morbidity and mortality; improvement in quality of life; and demonstrated cost-effectiveness.

Clinical evidence with sevelamer
================================

Numerous outcomes have been measured in the published evidence. The majority of the evidence related to disease-oriented outcomes, such as effects on serum phosphate, serum calcium, dyslipidemia, serum uric acid, metabolic acidosis, arterial calcification and bone mineral density. Patient-oriented outcomes included cardiovascular morbidity and mortality, improvement of calcific uremic arteriolopathy, and risk of hospitalization, but the evidence base for these outcomes was smaller.

Serum phosphate
---------------

The evidence demonstrates that sevelamer is effective in reducing serum phosphate from pretreatment (baseline) values. Most of the evidence (all five studies in the systematic review, and two of three further RCTs) shows that sevelamer is as effective as calcium salts in reducing serum phosphate, and that sevelamer alone is as effective as sevelamer plus supplemental calcium ([Table 5](#t5-ce-1-043){ref-type="table"}). However, one RCT ([@b65-ce-1-043]) reported that serum phosphate was significantly higher with sevelamer than with calcium acetate ([Table 5](#t5-ce-1-043){ref-type="table"}), although at 8 weeks' duration this study was shorter than most of the other trials \[six of the seven studies reviewed by [@b53-ce-1-043] were \>8 weeks\]. Furthermore, this study used a formulation of sevelamer (403 mg capsules) that is no longer available, and did not use a dose of sevelamer that was equipotent to the dose of calcium acetate. The [@b65-ce-1-043] study used a double-blind design, whereas the other comparisons between sevelamer and calcium salts were open label and thus could be considered weaker. However, blinding should have had little, if any, effect on objective measurements of absolute values such as serum phosphate. [@b65-ce-1-043] also used a different measure of serum phosphate, time-averaged serum phosphate over 1--8 weeks as opposed to mean change from baseline to end of treatment, compared with the other studies, and it is possible that this may account for the different results.

Serum calcium
-------------

[@b14-ce-1-043] found in their meta analysis that sevelamer had a small and statistically insignificant effect on serum calcium (see [Table 5](#t5-ce-1-043){ref-type="table"}). The results of the review by [@b53-ce-1-043] are consistent with this, as the four RCTs comparing sevelamer with calcium salts showed only small mean changes in serum calcium, ranging from an increase of 0.2 mg/dL to a decrease of 0.05 mg/dL with sevelamer ([@b53-ce-1-043]). This wide range may be due in part to variations in the dialysate calcium concentration utilized in the studies. In all four studies the mean increase with sevelamer was lower than with the calcium salt; the difference was statistically significant in three studies (*P*\<0.01) and not statistically significant in one study ([@b53-ce-1-043]). There was no statistically significant difference between sevelamer alone and sevelamer with supplemental calcium (see [Table 5](#t5-ce-1-043){ref-type="table"}).

On balance, the current evidence shows that sevelamer has little effect on serum calcium levels, and is less prone to increase serum calcium levels than calcium salts, although none of these trials was powered to detect a difference.

Incidence of hypercalcemia
--------------------------

There is strong evidence that sevelamer is associated with a statistically significantly (*P*\<0.01) lower incidence of hypercalcemia than calcium salts (both the trials in the systematic review that reported data on this outcome, and two of three further trials) (see [Table 5](#t5-ce-1-043){ref-type="table"}). Although one RCT reported no statistically significant difference between sevelamer and calcium acetate, it was not powered to detect a difference ([@b40-ce-1-043]).

Serum Ca × P product
--------------------

Most of the evidence demonstrates that sevelamer is as effective as calcium salts in decreasing serum Ca × P (see [Table 5](#t5-ce-1-043){ref-type="table"}). One exception, the RCT of [@b65-ce-1-043], reported that calcium acetate decreased Ca × P significantly more than sevelamer. However, as discussed in the section on serum phosphate, this study was of short duration compared with the others and used time-averaged concentrations rather than change from baseline to endpoint.

Parathyroid hormone
-------------------

Evidence from the meta analysis, systematic review, and two of three further RCTs shows that sevelamer was as effective as calcium salts in reducing serum PTH, and that addition of supplemental calcium did not produce a statistically significant difference (see [Table 5](#t5-ce-1-043){ref-type="table"}).

Intact PTH, the form measured in the studies in [Table 5](#t5-ce-1-043){ref-type="table"}, consists of 84 amino acids (1--84 PTH). The N-terminally-truncated molecule (7--84 PTH) may have different effects from the intact molecule, being associated with hypocalcemia and decreased bone turnover (rather than hypercalcemia and increased bone turnover). In a small study of 17 hemodialysis patients, sevelamer treatment for 5 weeks significantly (*P*=0.03) reduced serum 1--84 PTH, but had no statistically significant effect on 7--84 PTH ([@b24-ce-1-043]). The clinical significance of effects on different forms of PTH remains unresolved.

Vascular calcification
----------------------

There is evidence from the RCT conducted by the Treat to Goal Working Group ([@b21-ce-1-043]) that sevelamer is associated with significantly greater reductions in calcification scores (using electron beam tomography) than calcium salts after 52 weeks of treatment ([Table 6](#t6-ce-1-043){ref-type="table"}). Subanalyses of the primary study ([@b22-ce-1-043]; [@b10-ce-1-043]) found that this remained true when sevelamer was compared with either calcium acetate (US patients; [@b22-ce-1-043]) or calcium carbonate (German and Austrian patients; [@b10-ce-1-043]) (see [Table 6](#t6-ce-1-043){ref-type="table"}). The benefit in reduced calcification was greatest in patients with poorly controlled phosphate and Ca × P product ([@b10-ce-1-043]). A further analysis ([@b67-ce-1-043]) reported that mitral and aortic valve calcification scores were not significantly different between the treatment groups, but that significantly more sevelamer patients experienced a regression in total calcification burden (derived by combining vascular and valve calcification scores) compared with calcium-treated patients (see [Table 6](#t6-ce-1-043){ref-type="table"}).

A further subanalysis presented data from 150 patients in the Treat to Goal study who had electron beam tomography data at baseline and after either 26 or 52 weeks of treatment with sevelamer or calcium salts ([@b23-ce-1-043]). In patients treated with calcium salts, the change in coronary calcification was significantly correlated with serum phosphorus (r=0.22, *P*=0.04) and Ca × P product (r=0.26, *P*=0.02), and the change in aortic calcification was significantly correlated with serum calcium (r=0.28, *P*=0.01). None of the corresponding correlations were statistically significant in the sevelamer group ([@b23-ce-1-043]).

As discussed in the Disease overview section above, medial calcification is associated with arterial stiffening. A separate study in Japan measured the change in pulse wave velocity in 15 patients during the 6 months before they were switched from calcium carbonate to sevelamer and during the 6 months after the switch (level 3 evidence; [@b82-ce-1-043]). Increased pulse wave velocity indicates increased arterial stiffness ([@b50-ce-1-043]). In the 6 months before the switch, mean pulse wave velocity increased by 46 cm/s per month, while in the 6 months after switching to sevelamer pulse wave velocity decreased by 20 cm/s per month (*P*\<0.01 for comparison between the two periods). These findings indicate that calcium carbonate treatment was associated with a progressive increase in pulse wave velocity, which was reversed by sevelamer treatment ([@b82-ce-1-043]).

Calcific uremic arteriolopathy
------------------------------

An observational study reported data from eight patients with calcific uremic arteriolopathy (calciphylaxis) who were managed with zero-calcium dialysate and switched from calcium-based phosphate binders to sevelamer ([@b47-ce-1-043]). Six of the eight patients showed "dramatic improvement" (no criteria specified) in their skin lesions, according to the author, and four showed total healing ([@b47-ce-1-043]).

Case reports of three patients have described similar results. [@b69-ce-1-043] described a 73-year-old man with calcific uremic arteriolopathy and leg ulcerations, whose lesions healed after switching from calcium-based phosphate binders to sevelamer, discontinuing vitamin D analogs and receiving aggressive wound care. The healing was paralleled by a decrease in serum phosphate and Ca × P product ([@b69-ce-1-043]). [@b27-ce-1-043] described two women with calcific uremic arteriolopathy whose lesions healed after switching from calcium-based phosphate binders to sevelamer and undergoing more frequent hemodialysis with a low-calcium dialysate. This treatment also resulted in a reduction in serum phosphate and Ca × P product ([@b27-ce-1-043]).

These case reports and case series indicate that using sevelamer as part of a treatment regimen to reduce Ca × P product may have a beneficial effect in patients with calcific uremic arteriolopathy. However, it should be noted that other calcium-sparing phosphate binders may be equally effective, and no evidence has compared sevelamer with alternative noncalcium phosphate binding compounds in calcific uremic arteriolopathy.

Serum lipids
------------

Strong evidence shows that sevelamer significantly reduces low-density lipoprotein cholesterol (LDL cholesterol) and total cholesterol, and that it is significantly more effective on these outcomes than calcium salts ([Table 7](#t7-ce-1-043){ref-type="table"}).

Serum uric acid
---------------

Elevated serum uric acid concentrations are common in patients with advanced CKD and are associated with the development of gout, although clinically it is relatively insignificant. Nevertheless, evidence indicates that sevelamer treatment is associated with a statistically significant reduction in mean serum uric acid concentration compared with baseline, and in one RCT ([@b36-ce-1-043]) the reduction observed with sevelamer was greater than that observed with calcium salts ([Table 8](#t8-ce-1-043){ref-type="table"}).

Metabolic acidosis
------------------

Since some of the hydrochloride component of sevelamer is absorbed, this may theoretically promote the development of acidosis, in contrast to the calcium-based phosphate binders. Absorption of hydrochloride increases the amount of H^+^ ions absorbed (acid load); the H^+^ ions react with bicarbonate ions in the serum to form CO~2~ and water, reducing the serum bicarbonate concentration. If the excess CO~2~ can be removed by the lungs (respiratory compensation), the ratio between CO~2~ and bicarbonate (and hence blood pH) may be maintained within the normal range, although at lower absolute levels of CO~2~ and bicarbonate.

Evidence is divided on whether sevelamer lowers serum bicarbonate more than calcium salts ([Table 9](#t9-ce-1-043){ref-type="table"}). Of the studies reported in the systematic review, one showed no difference from placebo, one showed no difference between sevelamer with and without supplemental calcium, one showed no difference from calcium salts, and one showed lower serum bicarbonate with sevelamer compared with calcium salts (19.2 mmol/L vs 22.1 mmol/L, *P*\<0.0001). A further RCT reported that after 8 weeks of treatment, mean serum bicarbonate was significantly lower with sevelamer than with calcium acetate (19.3 mmol/L vs 21 mmol/L, *P*\<0.0001). A retrospective study in 17 patients treated with sevelamer for 2 years found that mean serum bicarbonate declined significantly during treatment (from 20 mEq/L to 17.9 mEq/L, *P*=0.002), while there was no statistically significant change in serum bicarbonate in seven control patients who received calcium- or aluminum-based phosphate binders for the same length of time ([@b79-ce-1-043]). This study also reported significant increases in serum potassium (from 5.45 mEq/L to 5.75 mEq/L, *P*=0.02) and mean intact parathyroid hormone (from 132.8 pg/mL to 326.9 pg/mL, *P*=0.0008) in the sevelamer-treated patients, with no statistically significant change in the controls, and the authors suggest that secondary hyperparathyroidism and elevated serum potassium could be related to metabolic acidosis. However, they also reported that correlations between serum bicarbonate changes and sevelamer dose, and between serum bicarbonate and intact parathyroid hormone, were not significant ([@b79-ce-1-043]). Two retrospective studies presented in abstract form reported that a higher proportion of sevelamer-treated patients had serum bicarbonate \<20 mmol/L compared with patients receiving calcium salts (see [Table 9](#t9-ce-1-043){ref-type="table"}), although since these studies were not randomized they may have been subject to selection bias.

A nonrandomized study reported in abstract form ([@b84-ce-1-043]) found that 2 years of treatment with sevelamer produced a reduction in the mean partial pressure of CO~2~ and a slight reduction in serum pH, though serum pH remained within the normal range (see [Table 9](#t9-ce-1-043){ref-type="table"}). This pattern is consistent with chronic metabolic acidosis in the sevelamer group (reflecting the increased acid load from the hydrochloride component), with respiratory compensation reducing the partial pressure of CO~2~ to maintain serum pH in the normal range.

Thus, it seems that sevelamer can produce modest reductions in serum bicarbonate, but does not consistently do so. It is not clear whether such reductions are of clinical significance; the K/DOQI guidelines recommend that serum total CO~2~ should not fall below 22 mmol/L ([@b60-ce-1-043]), but results from the DOPPS study found that a moderate acidosis (predialysis serum total CO~2~ levels of 20.1--22 mmol/L) was associated with a reduction in hospitalization and mortality risk ([@b9-ce-1-043]). As mentioned earlier, there is a lack of evidence on the clinical significance of acidosis, the impact of bicarbonate supplementation, and what constitutes an appropriate endpoint.

Gastrointestinal tolerability
-----------------------------

Gastrointestinal adverse events were not consistently defined and reported in the published studies. In the studies that provided some evidence on the occurrence of gastrointestinal adverse events for sevelamer compared with calcium salts the evidence was conflicting, with two studies reporting a higher incidence of gastrointestinal adverse events for sevelamer and four reporting no difference ([Table 10](#t10-ce-1-043){ref-type="table"}).

In a single-group study in 19 hemodialysis patients in Italy switched from calcium carbonate (with or without additional aluminum salts) to sevelamer, two patients withdrew because of gastrointestinal adverse events (one for diarrhea, one for nausea and heartburn), and a further patient reported dyspepsia as an adverse event ([@b35-ce-1-043]). A second single-group study in 27 hemodialysis patients in France reported that sevelamer treatment was associated with "minor but poorly tolerated adverse events" including constipation (32%), vague abdominal pain (27%), diarrhea (23%), and gastric dyspepsia (18%) ([@b41-ce-1-043]). The authors noted that the incidence of adverse events progressively diminished after the first few months of treatment, from 63% of patients after 1 month to 8% after 6 months, but commented that digestive adverse events were a barrier to compliance in their patients ([@b41-ce-1-043]). In a group of 34 patients switched to sevelamer for previously uncontrolled hyperphosphatemia, gastrointestinal complaints were reported in 23 patients (67%) ([@b2-ce-1-043]).

On balance, this suggests that sevelamer can be associated with the occurrence of troublesome gastrointestinal adverse events, but the evidence does not clearly show whether the incidence is higher with sevelamer than with calcium salts. Some of the earlier evidence of adverse gastrointestinal effects may have resulted from the high pill counts associated with the earlier sevelamer 403 mg formulation, rather than the 800.mg formulation now in use.

Bone mineral density
--------------------

Limited evidence, from a subanalysis of patients in the [@b21-ce-1-043] study for whom data on bone mineral density \[measured by computed tomography densitometry and expressed in Hounsfield Units (HU)\] were available at baseline and after 52 weeks of treatment, indicates that patients treated with calcium salts (n=68) experienced significant loss in trabecular bone mineral density during treatment (median absolute change from baseline −7.9 HU, *P*\<0.05), while sevelamer-treated patients (n=57) showed no loss of trabecular bone mineral density (median absolute change from baseline 0, *P*=NS) ([@b66-ce-1-043]). The difference between the two groups was statistically significant (*P*=0.01; [@b68-ce-1-043]). Further evidence is needed to confirm this finding and to investigate the influence of sevelamer on other aspects of bone morbidity (e.g. incidence of fractures and bone pain).

Cardiovascular morbidity and mortality
--------------------------------------

As arterial calcification is associated with increased mortality ([@b49-ce-1-043]), the reduction in arterial calcification observed with sevelamer compared with calcium salts could have important potential survival benefits. A modeling study ([@b42-ce-1-043]) has explored this area, using data on arterial calcification obtained from an RCT ([@b21-ce-1-043]) combined with data on cardiovascular risk from a cohort study. Multivariate regression analysis of the data from [@b21-ce-1-043] was used to develop an equation to predict the arterial calcification score from baseline clinical characteristics and medical history. This equation was then applied to data from a cohort of 179 patients from a single dialysis center in France, who were followed up for a mean of 4 years. The calcification score for each of these patients was estimated using the equation developed from the [@b21-ce-1-043] data, and this predicted score was then included in regression analysis of cardiovascular risk. The predicted calcification score was significantly associated (*P*\<0.0001) with the 4-year cardiovascular risk, and an equation was developed to estimate the cardiovascular risk from the calcification score ([@b42-ce-1-043]). Applying this equation to the calcification score data in the treatment groups from [@b21-ce-1-043] allowed the authors to estimate that in a population of 100 patients, treatment with sevelamer rather than calcium salts would prevent a total of nine cardiovascular events over the patients' lifetimes ([@b42-ce-1-043]).

Further results from this modeling study have been presented in abstract form ([@b15-ce-1-043]). This estimated that in a cohort of 100 patients, sevelamer treatment for 1 year would prevent nine future cardiovascular events and save 18 life-years compared with calcium acetate treatment, and prevent 10 future cardiovascular events and save 18 life-years compared with calcium carbonate ([@b15-ce-1-043]).

A retrospective study in dialysis patients receiving sevelamer (n=696), calcium acetate (n=4018), or calcium carbonate (n=3279) during 2001 reported data on cardiac mortality ([@b86-ce-1-043]). Among the sevelamer patients, 10.8% died of cardiac disease in 2001, compared with 16.6% of patients treated with calcium acetate (*P*\<0.001 vs sevelamer) and 12.6% of patients receiving calcium carbonate (*P*=NS vs sevelamer). However, this study was not randomized and the sevelamer group had a significantly (*P*\<0.001) lower mean age, a higher percentage of women and a higher percentage of patients on peritoneal dialysis compared with the other two groups ([@b86-ce-1-043]), which may have affected the results.

Sevelamer also sequesters bile acids and has been shown to reduce serum lipid levels; this action may also have favorable cardiovascular effects ([@b48-ce-1-043]).

Direct evidence from prospective RCT is required to fully assess the effect of sevelamer on cardiovascular mortality and morbidity.

Hospitalization
---------------

A case--control study compared rates of hospitalization in sevelamer-treated Medicare patients (n=152) enrolled in the study published by [@b19-ce-1-043] and nonsevelamer-treated Medicare patients (n=152) from the same dialysis facilities over the same time period, matched for age, sex, race, diabetic status, and geographic location ([@b26-ce-1-043]). After adjusting for prior medical history and severity of disease, Cox regression analysis showed a significant reduction in the risk of hospitalization for any reason in the 17-month study period in the sevelamer group (46--54% lower than in the control group, *P*\<0.03) ([@b26-ce-1-043]). However, significantly more of the control subjects had a history of cerebral vascular accidents or transient ischemic attacks and gastrointestinal disease associated with bleeding, compared with the sevelamer group. The sevelamer patients were selected from a clinical study population with defined inclusion/exclusion criteria, and the possibility that differences in the patient population may have biased the results cannot be excluded, as acknowledged by the authors ([@b26-ce-1-043]). Evidence from randomized trials is needed to assess this point.

Compliance
----------

One observational study presented data on compliance with phosphate binders ([@b83-ce-1-043]). Interviews were conducted with 188 dialysis patients (129 on hemodialysis), and found that 37.8% of patients admitted noncompliance with their phosphate binder (compliance defined as taking 80% of the tablets prescribed). The noncompliant patients were prescribed higher doses of phosphate binders than the compliant patients (9.3 vs 8.2 pills/day), but actually took smaller doses (4.2 vs 7.6 pills/day). Noncompliant and compliant patients did not differ with respect to the type of phosphate binder prescribed (categorized by the authors into calcium binders vs noncalcium binders) ([@b83-ce-1-043]). This study did not provide specific evidence on rates of compliance with sevelamer treatment. However, as the phosphate binder medication burden with sevelamer is not notably different from that with calcium salts (both require daily doses of several grams), little difference would be expected, and the findings of [@b83-ce-1-043] are consistent with this expectation.

Quality of life
---------------

No evidence was identified in the search on the effects of sevelamer on health-related quality of life.

Other comparisons
-----------------

A crossover study in six hemodialysis patients found that colestimide, a bile-acid sequestrant with a similar chemical structure to sevelamer, was significantly less effective than sevelamer as a phosphate binder ([@b81-ce-1-043]).

Combination treatment
---------------------

Concern has been expressed over the cost of sevelamer compared with calcium salts ([@b57-ce-1-043]; [@b53-ce-1-043]; [@b80-ce-1-043]). It has been suggested that combination treatment with low-dose sevelamer and low-dose calcium salts could achieve effective phosphate control at a lower cost ([@b39-ce-1-043]). There has also been concern that Japanese patients may be less tolerant of sevelamer treatment and more prone to develop hypocalcemia because average dietary calcium intake is lower in Japan than in Europe or the USA, leading to the suggestion that combination treatment may be a useful alternative in this population ([@b62-ce-1-043]). As the K/DOQI guidelines recommend targets for various parameters without specifying how these targets should be achieved, a number of investigators have examined combination therapy as a possible means of achieving K/DOQI targets.

[@b57-ce-1-043] selected 23 hemodialysis patients with hypercalcemia (serum calcium \>2.6 mmol/L), and exchanged 50% of their initial calcium binder dose for sevelamer. After 4 weeks, if serum calcium was still above 2.6 mmol/L, a further 50% of the calcium dose was replaced by sevelamer, and if serum calcium was normal but serum phosphate was \>2 mmol/L, the dose of sevelamer was increased by 25%. Patients were then followed for a further 4 weeks. Mean serum calcium declined significantly during the study (from 2.8 to 2.56 mmol/L, *P*\<0.0005), mean serum phosphate showed no statistically significant change, and mean intact PTH increased (from 166 to 276 ng/L, *P*=0.02). The percentage of patients with hypercalcemia declined from 100 to 26%. The mean sevelamer dose was 2.77 g/day and the mean calcium dose (measured as elemental calcium) was 1.03 g/day. The authors concluded that combination treatment could achieve control of serum phosphate without inducing hypercalcemia in the majority of patients who had been hypercalcemic on their previous phosphate binder treatment ([@b57-ce-1-043]).

A further study replaced part of the calcium binder dose with sevelamer in a group of 18 dialysis patients with serum phosphate \>1.8 mmol/L who were intolerant of other available phosphate binders ([@b80-ce-1-043]). Sevelamer was added at an initial dose of 403 mg three times daily and titrated to a maximum of 1209 mg three times daily. Mean serum phosphate and Ca × P product were significantly (*P*=0.02) lower after addition of sevelamer than before, with no significant change in serum calcium or PTH. The mean dose of sevelamer was 2.4 g/day and the mean dose of elemental calcium decreased from 3.4 g/day to 1.2 g/day (*P*=0.04).

A study in Japan treated a cohort of 210 patients with sevelamer plus calcium carbonate, gradually increasing the sevelamer dose and reducing the calcium carbonate dose over a period of 24 weeks ([@b74-ce-1-043]; [@b62-ce-1-043]). After 24 weeks, the sevelamer dose was further increased to 3.29 g/day and the calcium carbonate dose was decreased by 54%. Serum calcium significantly decreased (*P*=0.0012), although there was also a small increase in serum phosphate (from 5.89 mg/dL to 6.25 mg/dL, *P*=0.017) ([@b62-ce-1-043]). Among patients with a baseline PTH \<150 pg/mL, PTH and phosphate increased and serum calcium decreased compared with baseline (all *P*\<0.05); while in those with a baseline PTH 150--300 pg/mL, serum PTH increased without statistically significant changes in calcium or phosphate; and in those with a baseline PTH ≥300 pg/mL, there were no significant changes in serum PTH, calcium, or phosphate. Vitamin D treatment could be started or intensified in 23 of 66 patients with baseline PTH ≥300 pg/mL, because of improved calcium and phosphate control ([@b74-ce-1-043]). It is important to note that this study utilized sevelamer to introduce or escalate vitamin D therapy in order to avoid low calcium, which may have been the main determinant of serum calcium and phosphate levels. The overall doses of binder were low, which may explain the suboptimal control of serum phosphate.

Economic evidence
=================

The major cause of death in patients with CKD is cardiovascular disease ([@b55-ce-1-043]; [@b34-ce-1-043]). There is evidence that sevelamer can reduce the rate of progression of arterial calcification in hemodialysis patients compared with calcium salts, perhaps due to the lower incidence of hypercalcemia with sevelamer ([@b21-ce-1-043]), as discussed above in the Clinical evidence section. Arterial calcification has been linked to cardiovascular morbidity and mortality ([@b49-ce-1-043]), and thus a reduction would be expected to produce a corresponding reduction in cardiovascular events and deaths. Such an improvement in cardiovascular disease could potentially provide substantial economic benefits, which in turn could offset the higher acquisition price of sevelamer compared with calcium salts \[in the USA the mean annual cost of sevelamer was estimated at \$US3644 per patient, compared with \$US154 for calcium carbonate and \$US463 for calcium acetate ([@b53-ce-1-043])\].

The economic effects of the reduction in arterial calcification with sevelamer have been explored in a modeling study published in abstract form ([@b15-ce-1-043]). The model estimated cardiovascular disease risk by combining calcification scores for sevelamer and calcium salts, reported in an RCT ([@b21-ce-1-043]), with equations relating calcification score to cardiovascular disease risk derived from a cohort study. In a cohort of 100 patients, the model estimated that 1 year of sevelamer treatment would save 18 life-years and prevent nine future cardiovascular events that would have cost \$US205 600 to manage, resulting in a net cost of \$US37 900 for sevelamer compared with calcium acetate ([@b15-ce-1-043]). The corresponding values for sevelamer compared with calcium carbonate were 18 life-years, 10 cardiovascular events prevented that would have cost \$US226 700 to manage, and a net cost of \$US19 500. The incremental cost-effectiveness ratios for sevelamer compared with calcium acetate were \$US2200 per life-year gained and \$US4400 per cardiovascular event prevented; for sevelamer compared with calcium carbonate the corresponding values were \$US1100 per life-year gained and \$US2300 per cardiovascular event prevented ([@b15-ce-1-043]). The authors comment that these results show that sevelamer is highly cost-effective, as the median cost-effectiveness of dialysis is \$US46 000 per life-year gained ([@b15-ce-1-043]). However, there has been debate over the cost-effectiveness of sevelamer ([@b64-ce-1-043]), and direct evidence of the economic effects of sevelamer is required to confirm these estimates.

A case--control study reported that average total Medicare expenditure during the 17-month study was lower in patients receiving sevelamer than in matched controls not receiving sevelamer (\$US4422 vs \$US5866 per patient per month) ([@b26-ce-1-043]). However, there were baseline differences in the medical history of the two groups that may have affected the results, and these findings need to be replicated in randomized trials.

As discussed above in the Disease overview section, it has been suggested that dyslipidemia may be a major determinant of cardiovascular mortality in dialysis patients. A decision-analysis model estimated the costs and cost-effectiveness of sevelamer compared with calcium carbonate plus atorvastatin for reducing LDL cholesterol in patients with CKD ([@b12-ce-1-043]). The authors state that the modeled population represents patients with CKD, hyperphosphatemia, and dyslipidemia who are not yet on dialysis ([@b12-ce-1-043]). However, the sevelamer data used to populate the model were derived from seven published sevelamer trials, six of which were conducted in hemodialysis patients (the other was in healthy volunteers), so the study is relevant to a review of sevelamer in hemodialysis patients. The study estimated that the total annual cost of treatment with calcium carbonate (1 g three times per day) plus atorvastatin (10 mg/day) was \$US1029 per patient, while the cost of treatment with sevelamer (2 × 403 mg capsules three times per day) was \$US1579 per patient. The estimated percentage of patients achieving a 35% reduction in LDL cholesterol concentration was 74.2% in the calcium carbonate+atorvastatin group, and 50.2% in the sevelamer group. These results indicate that calcium carbonate+atorvastatin was both more effective and less costly than sevelamer for reducing LDL cholesterol in predialysis patients ([@b12-ce-1-043]).

However, the study has a number of serious limitations. First, although the modeled population is stated to be predialysis patients with hyperphosphatemia and dyslipidemia, the sevelamer data were derived from studies in healthy volunteers or hemodialysis patients, whereas the data for the calcium carbonate+atorvastatin group were derived from studies of atorvastatin alone in patients with hypercholesterolemia and/or cardiovascular risk factors without CKD. Thus, the efficacy data used to populate the model are derived from different patient populations, neither of which is the modeled population. Second, the sevelamer studies did not report data on the percentage of patients who achieved a 35% reduction in LDL cholesterol, so the authors assumed that the probability would be 50%. Third, the authors assumed that hypercalcemia was "generally not of concern" and did not consider possible effects of hypercalcemia on costs or effectiveness. Fourth, the model did not take account of any costs associated with adverse events. Fifth, the effectiveness data were derived from trials lasting 8--16 weeks (atorvastatin) or 15 days--44 weeks (sevelamer), and these data may not be capable of extrapolation to the modeled period of 1 year. Sixth, the choice of effectiveness measure (reduction in LDL cholesterol by 35%) relies on an assumption that this is a key determinant of cardiovascular risk in CKD patients and does not take account of other potential cardiovascular risk factors in these patients, such as arterial calcification score, elevated serum calcium, and/or Ca × P product. It is not unexpected that atorvastatin, designed and used specifically as a lipid-lowering agent, should prove to be more effective at lipid-lowering than sevelamer, which was designed and used as a phosphate binder. These limitations, most of which are acknowledged by the study authors, limit the potential applicability of the model's findings.

Some evidence indicates that sevelamer may be associated with better preservation of trabecular bone mineral density than calcium salts ([@b66-ce-1-043]). This may have the potential to save costs associated with the management of bone disease (e.g. costs of managing fractures or treating bone pain). However, direct evidence is required on this issue.

Further economic studies on a range of outcomes are required to evaluate the cost-effectiveness of sevelamer as a phosphate binder in hemodialysis patients.

Resource utilization
====================

The acquisition price of sevelamer is substantially higher than that of calcium salts. The potential budget impact of using sevelamer in all patients who meet the K/DOQI guideline criteria for its use (see Patient population section below) has been estimated for the USA and Canada ([@b53-ce-1-043]). In Canada, 51% of a cohort of dialysis patients (407 hemodialysis, 92 peritoneal dialysis) met the K/DOQI criteria for use of sevelamer. Extrapolating this figure to the total Canadian dialysis population, the authors estimated that using sevelamer in all patients meeting the K/DOQI criteria would result in an expenditure of \$US26 million per year on sevelamer. Of a cohort of 1600 hemodialysis patients and 400 peritoneal dialysis patients in the USA, 64% met the K/DOQI criteria for sevelamer use, and extrapolating this to the total US dialysis population projected that \$US781 million per year would be spent on the drug ([@b53-ce-1-043]). The authors estimated that hospitalization costs for ESRD patients would have to be reduced by 45% in Canada and by considerably more (detailed estimate not provided) in the USA to offset the additional cost of sevelamer ([@b53-ce-1-043]).

It has been suggested that using a combination of sevelamer and a low dose of calcium salts may be effective in controlling serum phosphate and result in a lower cost than with sevelamer alone ([@b39-ce-1-043]), but there is little evidence on this point at present.

Sevelamer has been shown to attenuate the progression of arterial calcification compared with calcium salts, which has the potential to reduce the excess cardiovascular morbidity and/or mortality seen in hemodialysis patients. A modeling study has estimated that sevelamer treatment could reduce the costs of managing cardiovascular events in a cohort of 100 patients by \$US205 600 compared with calcium acetate and \$US226 700 compared with calcium carbonate ([@b15-ce-1-043]). These savings offset most of the additional acquisition cost of sevelamer, resulting in net costs for the cohort of \$US37 900 compared with calcium acetate and \$US19 500 compared with calcium carbonate ([@b15-ce-1-043]). Direct evidence is required to confirm these potential savings in cardiovascular treatment costs.

A case--control study has estimated that the risk of hospitalization over the 17-month study period was 46--54% lower in US Medicare patients treated with sevelamer compared with matched controls receiving other phosphate binders (Collins et al. 2001), and this could indicate substantial potential savings in direct treatment costs for patients receiving sevelamer. However, as previously discussed, this study reported significant baseline differences in medical history between the two groups, which may have influenced its results.

Prevention of cardiovascular morbidity should also reduce indirect costs (e.g. more patients may be able to work and/or undertake normal activities) and provide intangible benefits (e.g. improved quality of life), but the search identified no direct evidence relating to these potential economic benefits.

There is, at the time of writing, insufficient evidence to estimate the overall effect of sevelamer on resource utilization. Some evidence from retrospective and modeling studies suggests that higher expenditure in the drug budget (which follows from the higher acquisition cost of sevelamer compared with calcium salts) could be offset by savings elsewhere or justified by additional health benefits, but this needs to be confirmed by direct evidence from prospective controlled studies designed to measure economic endpoints.

Patient group/population
========================

Sevelamer is indicated for the treatment of adult patients on hemodialysis. While it may have potential benefits for other groups, such as children, patients on peritoneal dialysis, or predialysis patients, such off-label use is outside the scope of this review.

The NKF K/DOQI guidelines recommend sevelamer as a phosphate binder in the following clinical situations: In dialysis patients who remain hyperphosphatemic (serum phosphate \>5.5 mg/dL) despite the use of calcium-based binders or other noncalcium-, nonaluminum-, nonmagnesium-containing binders, a combination should be usedIn dialysis patients, the total dose of elemental calcium from calcium-based phosphate binders should not exceed 1500 mg/day. For comparison, the recommended daily dose of calcium acetate (3--4 capsules three times per day) equates to 1521--2028 mg/day elemental calcium (PhosLo ^®^ US package insert <http://www.fda.gov/cder/foi/label/2001/21160lbl.pdf>)In dialysis patients, calcium-based binders should not be used in patients with hypercalcemia (serum calcium \>10.2 mg/dL) or with serum PTH \<150 pg/mLIn dialysis patients with severe soft-tissue calcifications, noncalcium-based phosphate binders are preferredAdynamic bone disease should be treated by increasing PTH to ≥100 pg/mL by decreasing or eliminating calcium-based phosphate binders.

It has been estimated that 64% of US and 51% of Canadian dialysis patients would meet the K/DOQI criteria for the use of sevelamer ([@b53-ce-1-043]).

Patients with uncontrolled hyperphosphatemia
--------------------------------------------

A study in 34 patients with uncontrolled hyperphosphatemia (serum phosphate \>6.5 mg/dL and/or toxicity or intolerance to calcium- or aluminum-based phosphate binders) found that the addition of sevelamer provided better control of serum phosphate and Ca × P product and allowed a reduction in the dose of other binders ([@b2-ce-1-043]). However, 13 of 34 patients (38%) dropped out because of intolerance to sevelamer, mainly (no number or percentage specified) due to gastrointestinal adverse effects ([@b2-ce-1-043]). In a crossover study of 10 patients with uncontrolled hyperphosphatemia (serum phosphate 6.6--10.4 mg/dL), the effect of sevelamer on serum phosphate was similar to that of standard phosphate binders ([@b4-ce-1-043]). A study in 18 patients with hyperphosphatemia \[serum phosphate \>1.8 mmol/L (\>5.6 mg/dL)\] who were intolerant of other currently available phosphate binders found that combination treatment with sevelamer and calcium carbonate reduced serum phosphate and Ca × P product significantly (*P*=0.02) more than calcium carbonate alone ([@b80-ce-1-043]).

Patients with severe secondary hyperparathyroidism
--------------------------------------------------

In 18 patients with severe secondary hyperparathyroidism (mean serum intact PTH concentration 810 pg/mL), switching to sevelamer produced significant (*P*\<0.05) reductions in serum phosphate and serum calcium, with no change in PTH, leading the authors to conclude that sevelamer is an effective phosphate binder in such patients ([@b16-ce-1-043]). A further study, in which sevelamer replaced aluminum hydroxide in 11 hemodialysis patients with secondary hyperparathyroidism, reported that sevelamer significantly reduced mean serum phosphate and mean serum intact PTH after 8 weeks (both *P*\<0.003), but that there was no statistically significant change in mean serum calcium ([@b59-ce-1-043]).

Patients taking concurrent vitamin D and/or calcium supplements
---------------------------------------------------------------

A subgroup analysis of a cohort of patients who received sevelamer for 1 year ([@b19-ce-1-043]) found that sevelamer significantly reduced serum phosphate and Ca × P regardless of whether patients were also taking vitamin D, calcium supplements, or both ([@b20-ce-1-043]).

Japanese patients
-----------------

It has been suggested that Japanese patients may be less tolerant of sevelamer treatment and more prone to develop hypocalcemia because average dietary calcium intake is lower in Japan than in Europe or the USA ([@b62-ce-1-043]). A cohort study in 210 hemodialysis patients in Japan concluded that a combination of sevelamer and calcium carbonate could reduce calcium load compared with calcium carbonate alone, while still avoiding the development of hypocalcemia ([@b62-ce-1-043]).

Dosage, administration, and formulations
========================================

Sevelamer (Renagel^®^) is indicated for the control of hyperphosphatemia in adult patients on hemodialysis. It is available as film-coated tablets each containing sevelamer 800 mg.

For patients who are not taking phosphate binders and whose serum phosphate concentration is 1.94--2.42 mmol/L, the recommended starting dose is 1 × 800 mg tablet three times daily, increasing to 2 × 800 mg tablets three times daily if the serum phosphate concentration is \>2.42 mmol/L. In patients who are being switched from alternative phosphate binders, the starting dose of sevelamer should be the milligram equivalent of the patient's previous dose of calcium-based phosphate binder. Serum phosphate concentrations should be measured every 2--3 weeks, and the dose of sevelamer titrated with the goal of reaching a serum phosphate concentration of 1.94 mmol/L or less. The dose range may vary between 1 and 5 × 800 mg tablets three times daily. Sevelamer should be taken with meals ([@b3-ce-1-043]).

Place in therapy
================

The evidence summary table at the beginning of the article summarizes the clinical evidence for the impact of sevelamer on clinical and economic outcome measures. The strongest evidence was found for disease-oriented outcomes, such as arterial calcification score and reduction of serum phosphate, calcium and lipid concentrations. Although these may be markers of beneficial effects on patient-oriented outcomes (e.g. arterial calcification may be linked to a reduction in cardiovascular morbidity and mortality), in themselves they do not demonstrate improved length or quality of life. The evidence on patient-oriented outcomes was less clear. There was an indication of reduced cardiovascular mortality and morbidity, but the evidence on this outcome is derived from a modeling study and requires confirmation by direct observation. Among other patient-oriented outcomes, sevelamer may reduce hospitalization risk but this is derived from a case--control study and requires confirmation by randomized trials. Limited evidence from case reports and a small observational study suggests that reduction of Ca × P product by treatment interventions including sevelamer may improve healing of ulcers associated with calcific uremic arteriolopathy. This is of clear potential benefit to patients with this uncommon but serious and distressing condition, but it should be noted that there is no evidence comparing sevelamer with other noncalcium binders.

There is strong evidence that sevelamer is as effective as calcium salts in lowering serum phosphate and serum Ca × P product, with only one study finding to the contrary. Similarly, there is strong evidence that sevelamer is associated with a lower incidence of hypercalcemia than calcium salts. Only one study failed to show a statistically significant difference in hypercalcemia incidence in favor of sevelamer, and this study was not powered to detect a difference ([@b40-ce-1-043]). There is also strong evidence that sevelamer reduces LDL cholesterol more than calcium salts, with no results to the contrary.

Some evidence indicates that sevelamer reduces serum bicarbonate concentration more than calcium salts. Two studies have reported no statistically significant difference, but neither was powered on this endpoint. Data from a small single-group study, reported in abstract form, indicates that respiratory compensation (reduction in partial pressure of CO~2~) maintains serum pH in the normal range.

Evidence from one RCT (and several subanalyses) from the Treat to Goal Working Group study shows that sevelamer reduces the progression of arterial calcification compared with calcium salts. There is limited evidence that may indicate a beneficial effect of sevelamer as part of a therapeutic regimen for the management of calcific uremic arteriolopathy, with improvement and/or healing of ulcerations reported in a small observational study and two case reports. Some evidence also indicates that sevelamer reduces serum uric acid concentrations to a greater degree than calcium salts.

The attenuation of arterial calcification is potentially of great therapeutic value, as this has been suggested as a possible mechanism underlying the excess cardiovascular morbidity and mortality in CKD patients. A modeling study has estimated that the reduction in arterial calcification associated with sevelamer treatment could prevent 9--10 future cardiovascular events and save 18 life-years in a cohort of 100 patients. A retrospective study has also observed lower cardiac mortality in sevelamer-treated patients than in those receiving calcium acetate, although the study was not randomized and there were baseline differences between the groups that could have affected the results. Similarly, sevelamer was associated with a lower risk of hospitalization than calcium salts in a case--control study, but this study could also have been biased by significant differences between the groups at baseline.

A subanalysis of data from one RCT showed that sevelamer could preserve trabecular bone mineral density compared with calcium salts. This may suggest a beneficial effect on bone morbidity, but direct evidence is needed to confirm this possibility.

The evidence is divided with regard to the incidence of gastrointestinal adverse events, with six studies providing some comparison between sevelamer and calcium salts, two of which found that sevelamer was associated with a higher frequency of gastrointestinal adverse events than calcium salts while four reported no statistically significant difference. However, the evidence is limited in its applicability, since there was no consistent definition of gastrointestinal adverse events across the studies and so it is difficult to draw a firm conclusion about where the balance lies. Moreover, all but one of the studies were open label, a design known to be subject to potential bias in the reporting of subjective events. It may be significant that the one double-blind comparative study ([@b65-ce-1-043]) reported no statistically significant difference between sevelamer and calcium acetate in subjective symptom scores for gastrointestinal adverse events, although the study was not powered to detect a difference. Further evidence on this point is required. No evidence was identified in this review on the effect of sevelamer on quality of life.

Limited evidence from one study suggested that the phosphate binder medication burden and patient adherence to therapy was no different with sevelamer than with calcium salts. Although this evidence is weak in itself, it is consistent with the fact that average doses of sevelamer are several grams per day, which is not dissimilar to the doses of calcium salts. No marked improvement in phosphate binder medication burden would thus be expected.

Considering economic evidence, it is clear that the acquisition cost of sevelamer is higher than that of calcium salts. However, a modeling study estimated that this increased acquisition cost could be largely offset by reduced cardiovascular mortality and morbidity, and estimated the incremental cost-effectiveness ratio for sevelamer compared with calcium salts at \$US1100--2200 per life-year gained. However, direct evidence is needed to confirm these estimates before the true economic benefits and cost-effectiveness of sevelamer can be assessed.

In summary, there is strong evidence that sevelamer is as effective as calcium salts in controlling serum phosphate and Ca × P product, has less risk of inducing hypercalcemia, and is more effective at lowering lipid levels. Some evidence also indicates that sevelamer is more effective than calcium salts in reducing the progression of arterial calcification, which may in turn be associated with reduced cardiovascular mortality and/or morbidity. It has been estimated that savings in treatment costs associated with cardiovascular events could offset most of the additional acquisition cost of sevelamer compared with calcium salts. However, direct evidence is required to confirm the effects of sevelamer on cardiovascular morbidity and mortality and to assess its cost-effectiveness.

![Pathogenesis of hyperphosphatemia and abnormalities of mineral and bone metabolism in chronic kidney disease. Ca, calcium; GFR, glomerular filtration rate; PTH, parathyroid hormone](ce-1-043f1){#f1-ce-1-043}

###### 

Evidence base included in the review

  **Category**                    **Number of records**   
  ------------------------------- ----------------------- -----
  Initial search                  142                     35
    records excluded              114                     19
    records included              28                      16
  Additional studies identified   3                       n/a
  Search update, new records      23                      0
    records excluded              17                      
    records included              6                       
  Total records included          37                      16
  Level 1 clinical evidence       2                       0
  Level 2 clinical evidence       11                      1
  Level ≥3 clinical evidence      22                      14
    trials other than RCT         20                      14
    case studies                  2                       0
  Economic evidence               2                       1

RCT, randomized controlled trial

###### 

Main currently available phosphate binders (adapted from [@b48-ce-1-043]; [@b31-ce-1-043])

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug class**                              **Compound**                             **Phosphate-binding effects**                         **Disadvantages**                                                            
  ------------------------------------------- ---------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Nonaluminum, noncalcium phosphate binders   Sevelamer                                Not available                                         77.5--84 mg                                                                  Large doses required (5--7 g/day)\
                                                                                                                                                                                                                          Gastrointestinal effects at high doses, similar frequency to high-dose calcium salts\
                                                                                                                                                                                                                          Absorption of released hydrochloride may contribute to metabolic acidosis

  Aluminum salts                              Aluminum hydroxide, aluminum carbonate   Normal subjects: 18%\                                 Not available                                                                Large doses required\
                                                                                       Dialysis patients: 35--49%                                                                                                         Unpleasant taste\
                                                                                                                                                                                                                          Can cause constipation\
                                                                                                                                                                                                                          Aluminum accumulation and toxicity to skeleton, central and peripheral nervous system, parathyroid glands, and hematopoietic cells

  Calcium salts                               Calcium carbonate                        Normal subjects: 44%                                  4.65--17 mg                                                                  Large doses required (8--10 g/day)\
                                                                                                                                                                                                                          Poor phosphate binding at neutral pH\
                                                                                                                                                                                                                          Hypercalcemia reported in one-third of patients

  Calcium acetate                             Normal subjects: 26%                     6.76--27 mg[b](#tfn3-ce-1-043){ref-type="table-fn"}   Large doses required (6--8 g/day)[c](#tfn4-ce-1-043){ref-type="table-fn"}\   
                                                                                                                                             Gastrointestinal effects can occur\                                          
                                                                                                                                             May be associated with hypercalcemia                                         

  Lanthanum salts                             Lanthanum carbonate                      Not available                                         Not available                                                                Moderate doses required (1.5--3 g/day)[d](#tfn5-ce-1-043){ref-type="table-fn"}\
                                                                                                                                                                                                                          Gastrointestinal adverse events can occur[d](#tfn5-ce-1-043){ref-type="table-fn"}\
                                                                                                                                                                                                                          Small amounts of lanthanum are absorbed and there is a possibility of accumulation with chronic use; long-term safety data are needed to assess this
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Without phosphate binders, 66--77% of dietary phosphate is absorbed ([@b31-ce-1-043]).

Original reference ([@b48-ce-1-043]) gives the lower end of the range as 46.76, but this does not agree with the mmol value given in the same source, which is 0.218. However, a value of 6.76 mg for the lower end of the range does match the mmol value.

Source: PhosLo^®^ US package insert.

Source: Fosrenol^®^ prescribing information (available at: <http://www.fosrenol.com/prescribingInfo.pdf>).

###### 

Phosphate binder usage (values may not sum as patients may have been taking more than one agent. The USRDS data were collected prior to 1996 and pre-date the introduction of sevelamer)

                                              **[@b51-ce-1-043]**                          **[@b52-ce-1-043] (DCI)**                           **[@b52-ce-1-043] (USRDS)**
  ------------------------------------------- -------------------------------------------- --------------------------------------------------- -----------------------------------------------------
  Patient population                          1312 HD patients from 7 centers in Spain     10 474 HD patients treated at DCI units in the US   Data on a sample of 1998 HD patients from the USRDS
  **Phosphate binder used (% of patients)**                                                                                                    
  Any phosphate binder                        71%                                          88%                                                 80%
  Calcium acetate                             NR[a](#tfn6-ce-1-043){ref-type="table-fn"}   43.4%                                               35%
  Calcium carbonate                           NR[a](#tfn6-ce-1-043){ref-type="table-fn"}   24%                                                 35%
  Any calcium salt                            51%                                          NR                                                  NR
  Sevelamer                                   21%                                          31.1%                                               NR
  Aluminum                                    16%                                          2.8%                                                6.1--10%

Original source did not distinguish between individual calcium salts.

DCI, Dialysis Centre Inc; HD, hemodialysis; NR, not reported; USRDS, United States Renal Data System.

###### 

NKF K/DOQI targets for parameters of calcium--phosphate balance in patients with CKD stage 5 (adapted from [@b60-ce-1-043])

  **Parameter**                                              **Target**
  ---------------------------------------------------------- ------------
  Serum phosphate (mg/dL)                                    3.5--5.5
  Serum calcium (mg/dL)                                      8.4--9.5
  Serum Ca × P (mg^2^/dL^2^)                                 \<55
  Serum intact PTH (pmol/L)                                  150--300
  Elemental calcium intake from phosphate binders (mg/day)   ≤1500

Ca × P, calcium--phosphate product; PTH, parathyroid hormone.

###### 

Effects of sevelamer on serum phosphate, calcium (Ca), calcium--phosphate product (Ca × P), parathyroid hormone (PTH), and incidence of hypercalcemia

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Level of evidence**   **Design**                                                                               **Treatment and mean dose**       **Outcome**                                                                **Reference**                                                                                                                                                                                                                                                                                                                   
  ----------------------- ---------------------------------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -----------------
  1                       Meta analysis                                                                            Sevelamer                         Mean decrease 2.14 mg/dL vs baseline (*P*\<0.001) (11 studies)             Mean increase 0.09 mg/dL vs baseline (NS) (9 studies)                     NR                                                          Mean decrease 15.9 mg^2^/dL^2^ vs baseline (*P*\<0.001) (9 studies)        Mean decrease 35.99 pg/mL vs baseline (*P*=0.026) (3 studies)                                                  [@b14-ce-1-043]

  1                       Systematic review                                                                        Sevelamer\                        Lower with S vs placebo (*P*\<0.04) (1 study)\                             NSD S vs placebo (1 study)\                                               Lower with S vs CaAc or CaCO~3~ (*P*\<0.0001) (2 studies)   NSD S vs Ca salts (3 studies)\                                             NSD S vs Ca salts (4 studies)\                                                                                 [@b53-ce-1-043]
                                                                                                                   Sevelamer plus supplemental Ca\   NSD S vs Ca salts (4 studies)\                                             NSD S vs CaCO~3~ (1 study)\                                                                                                           NSD S vs S+Ca (1 study)                                                    NSD S vs S+Ca (1 study)                                                                                        
                                                                                                                   Placebo\                          NSD S vs S+Ca (1 study)                                                    NSD S vs S+Ca (1 study)\                                                                                                                                                                                                                                                                                                        
                                                                                                                   CaAc\                                                                                                        Smaller increase with S vs Ca salts (*P*\<0.01) (3 studies)                                                                                                                                                                                                                                                                     
                                                                                                                   CaCO~3~                                                                                                                                                                                                                                                                                                                                                                                                                                      

  2                       Open, RCT, 34 weeks, n=40 in total                                                       Sevelamer 4.09 g/day\             Similar decrease for S and CaAc[b](#tfn10-ce-1-043){ref-type="table-fn"}   NSD vs baseline for S and CaAc[b](#tfn10-ce-1-043){ref-type="table-fn"}   NSD S vs CaAc                                               Similar decrease for S and CaAc[b](#tfn10-ce-1-043){ref-type="table-fn"}   Similar decrease for S and CaAc[b](#tfn10-ce-1-043){ref-type="table-fn"}                                       [@b40-ce-1-043]
                                                                                                                   CaAc 3.9 g/day                                                                                                                                                                                                                                                                                                                                                                                                                               

  2                       Open, RCT, 52 weeks, n=36 (S), n=46 (CaCO~3~)[c](#tfn11-ce-1-043){ref-type="table-fn"}   Sevelamer 5.9 g/day\              NSD S vs CaCO~3~                                                           Smaller increase with S vs CaCO~3~ (*P*\<0.01)                            Lower with S vs CaCO~3~ (*P*\<0.01)                         NSD S vs CaCO~3~                                                           Decrease for CaCO~3~ vs baseline (*P*\<0.01); NSD vs baseline for S[b](#tfn10-ce-1-043){ref-type="table-fn"}   [@b10-ce-1-043]
                                                                                                                   CaCO~3~ 3.9 g/day                                                                                                                                                                                                                                                                                                                                                                                                                            

  2                       Double-blind, RCT, 8 weeks, n=50 (S), n=48 (CaAc)                                        Sevelamer 6.9 g/day\              Higher with S vs CaAc (*P*=0.0006)                                         Lower with S vs CaAc (*P*\<0.0001)                                        Lower with S vs CaAc (*P*\<0.0001)                          Higher with S vs CaAc (*P*=0.022)                                          NSD S vs CaAc                                                                                                  [@b65-ce-1-043]
                                                                                                                   CaAc 7.1 g/day                                                                                                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Definition varied between studies; 2.8 mmol/L = 11.2 mg/dL.

No between-group statistical comparison reported.

Ninety-three of the 114 patients randomized were included in the primary publication of the Treat To Goal study ([@b21-ce-1-043]), which was one of the studies included in [@b53-ce-1-043].

CaAc, calcium acetate; CaCO~3~, calcium carbonate; NR, not reported; NS, not statistically significant; NSD, no statistically significant difference; RCT, randomized controlled trial; S, sevelamer.

###### 

Effects of sevelamer compared with calcium salts on vascular calcification (all level 2 evidence)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Design**                                                                                                                                                                **Treatment and mean dose**   **Outcome**                                 **Reference**                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ------------------------------------------- --------------------------------------------- ----------------------------------------- ----------------------------------------- ---------------------------------------- --------------------------------------- -----------------
  Open, 52 weeks, n=62 (S), n=70 (Ca salts)[a](#tfn13-ce-1-043){ref-type="table-fn"}                                                                                        Sevelamer 6.5 g/day\          S decrease 46\                              S decrease 532\                               NR                                        NR                                        NR                                       NR                                      [@b21-ce-1-043]
                                                                                                                                                                            Ca salts 4.3 g/day            Ca salts increase 151                       Ca salts increase 185                                                                                                                                                                                              

  Calcification score assessor blinded to study treatment                                                                                                                                                 (*P*\<0.04 S vs Ca salts)                   (*P*=0.01 S vs Ca salts)                                                                                                                                                                                           

  Subanalysis of [@b21-ce-1-043], US patients only, n=108 randomized                                                                                                        Sevelamer 6.7 g/day\          S increase 64 (NS vs baseline)\             S decrease 127 (NS vs baseline)\              NR                                        NR                                        NR                                       NR                                      [@b22-ce-1-043]
                                                                                                                                                                            CaAc 4.6 g/day                CaAc increase 182 (*P*=0.002 vs baseline)   CaAc increase 181 (*P*\<0.0001 vs baseline)                                                                                                                                                                        

  Subanalysis of [@b21-ce-1-043], German and Austrian patients, with 11 additional patients randomized, n=36 (S), n=46 (CaCO~3~)[a](#tfn13-ce-1-043){ref-type="table-fn"}   Sevelamer 5.9 g/day\          S decrease 130\                             S decrease 897\                               NSD vs baseline for S and CaCO~3~         NSD vs baseline for S and CaCO~3~         NR                                       NR                                      [@b10-ce-1-043]
                                                                                                                                                                            CaCO~3~ 3.9 g/day             CaCO~3~ increase 200\                       CaCO~3~ increase 240\                                                                                                                                                                                              
                                                                                                                                                                                                          (*P*=0.02 S vs CaCO~3~)                     (*P*\<0.01 S vs CaCO~3~)                                                                                                                                                                                           

  Re-analysis of [@b21-ce-1-043], to include data on heart valve calcification                                                                                              Sevelamer 6.5 g/day\          NR                                          NR                                            S decrease 655\                           S increase 24\                            S 45%\                                   S 26%\                                  [@b67-ce-1-043]
                                                                                                                                                                            Ca salts 4.3 g/day                                                                                                      Ca salts increase 98 (NS S vs Ca salts)   Ca salts increase 24 (NS S vs Ca salts)   Ca salts 28% (*P*=0.047 S vs Ca salts)   Ca salts 10% (*P*=0.02 S vs Ca salts)   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients with data at 52 weeks.

Ca, calcium; CaAc, calcium acetate; CaCO~3~, calcium carbonate; NR, not reported; NS, not statistically significant; NSD, no statistically significant difference; S, sevelamer.

###### 

Effects of sevelamer on serum low-density lipoprotein (LDL) cholesterol and total cholesterol

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Level of evidence**   **Design**                                                                               **Treatment and mean dose**   **Outcome**                                                           **Reference**                                                         
  ----------------------- ---------------------------------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------- -----------------
  1                       Meta analysis (10 studies)                                                               Sevelamer                     Mean decrease 31.38 mg/dL vs baseline (*P*\<0.001)                    Mean decrease 30.58 mg/dL vs baseline (*P*\<0.001)                    [@b14-ce-1-043]

  1                       Systematic review                                                                        Sevelamer\                    Lower with S vs placebo (1 study)\                                    Lower with S vs placebo (1 study)\                                    [@b53-ce-1-043]
                                                                                                                   Placebo\                      Lower with S vs Ca salts (3 studies)                                  Lower with S vs Ca salts (2 studies)                                  
                                                                                                                   CaAc\                                                                                                                                                                     
                                                                                                                   CaCO~3~                                                                                                                                                                   

  2                       Open, RCT, 34 weeks, n=40 in total                                                       Sevelamer 4.09 g/day\         Decrease vs baseline for S (*P*\<0.05); NSD vs baseline for CaAc      Decrease vs baseline for S (*P*\<0.05); NSD vs baseline for CaAc      [@b40-ce-1-043]
                                                                                                                   CaAc 3.9 g/day                                                                                                                                                            

  2                       Open, RCT, 52 weeks, n=36 (S), n=46 (CaCO~3~)[a](#tfn15-ce-1-043){ref-type="table-fn"}   Sevelamer 5.9 g/day\          Decrease vs baseline for S (*P*\<0.01); NSD vs baseline for CaCO~3~   Decrease vs baseline for S (*P*\<0.01); NSD vs baseline for CaCO~3~   [@b10-ce-1-043]
                                                                                                                   CaCO~3~ 3.9 g/day                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ninety-three of the 114 patients randomized were included in the primary publication of the Treat To Goal study ([@b21-ce-1-043]), which was one of the studies included in [@b53-ce-1-043].

Ca, calcium; CaAc, calcium acetate; CaCO~3~, calcium carbonate; NSD, no statistically significant difference; RCT, randomized controlled trial; S, sevelamer.

###### 

Effects of sevelamer on serum uric acid

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Level of evidence**   **Design**                                                                                 **Treatment and mean dose**                                                              **Outcome**                                       **Reference**                                                                                                
  ----------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------- -------------------------- ------------------------------------- ------------------------------------------- -----------------
  2                       Open, RCT, 52 weeks, n=81 (S), n=88 (Ca salts)[b](#tfn18-ce-1-043){ref-type="table-fn"}\   Sevelamer 6.5 g/day\                                                                     S decrease 0.64 mg/dL\                            S 23%\                     NR                                    NR                                          [@b36-ce-1-043]
                          Subanalysis of [@b21-ce-1-043]                                                             Ca salts[c](#tfn19-ce-1-043){ref-type="table-fn"}                                        Ca salts decrease 0.26 mg/dL\                     Ca salts 10%\                                                                                                
                                                                                                                                                                                                              (*P*=0.03 S vs Ca salts)                          (*P*=0.02 S vs Ca salts)                                                                                     

  2                       Open, RCT, 52 weeks, n=36 (S), n=46 (CaCO~3~)[b](#tfn18-ce-1-043){ref-type="table-fn"}     Sevelamer 5.9 g/day\                                                                     S decrease 40 μmol/L (*P*\<0.0001 vs baseline)\   NR                         NR                                    NR                                          [@b10-ce-1-043]
                                                                                                                     CaCO~3~ 3.9 g/day                                                                        CaCO~3~ NR                                                                                                                                                     

  3                       Open, 12 weeks, n=18 patients with severe secondary hyperparathyroidism                    Sevelamer                                                                                NR                                                NR                         Decrease 9% (*P*\<0.05 vs baseline)   NR                                          [@b16-ce-1-043]

  3                       Switching study in 45 patients                                                             Standard phosphate binders for 6 months, then 1 month cotreatment, then S for 6 months   NR                                                NR                         NR                                    S 5.9 mg/dL Standard binders 7 mg/dL\       [@b72-ce-1-043]
                                                                                                                                                                                                                                                                                                                                 (*P*=0.0001, S period vs standard period)   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Defined by the authors as a reduction of 1.5 mg/dL or more.

Patients for whom both baseline and follow-up data were available.

Mean dose not given, but in the primary analysis ([@b21-ce-1-043]), the mean dose was 4.3 g/day.

Ca, calcium; CaCO~3~, calcium carbonate; NR, not reported; RCT, randomized controlled trial; S, sevelamer.

###### 

Effects of sevelamer on measures of metabolic acidosis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Level of evidence**   **Design**                                                                                                                                                                                                  **Treatment and mean dose**       **Outcome**                                                          **Reference**                                                                                                                                 
  ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------- --------------------------- ---------------------------------------------------- ------------------------------------------------------------ -----------------
  1                       Systematic review                                                                                                                                                                                           Sevelamer\                        NSD S vs placebo (1 study)\                                          NR                          NR                                                   NR                                                           [@b53-ce-1-043]
                                                                                                                                                                                                                                      Sevelamer plus supplemental Ca\   NSD S vs CaCO~3~ (1 study)\                                                                                                                                                                                        
                                                                                                                                                                                                                                      Placebo\                          NSD S vs S+Ca (1 study)\                                                                                                                                                                                           
                                                                                                                                                                                                                                      CaAc\                             Lower with S vs Ca salts (*P*\<0.0001) (1 study)                                                                                                                                                                   
                                                                                                                                                                                                                                      CaCO~3~                                                                                                                                                                                                                                              

  2                       Double-blind, RCT, 8 weeks, n=50 (S), n=48 (CaAc)                                                                                                                                                           Sevelamer 6.9 g/day\              Lower with S vs CaAc (*P*\<0.0001)                                   NR                          NR                                                   NR                                                           [@b65-ce-1-043]
                                                                                                                                                                                                                                      CaAc 7.1 g/day                                                                                                                                                                                                                                       

  3                       Retrospective, 2 years, n=17 (S), n=7 (Ca or Al salts)                                                                                                                                                      Sevelamer\                        Decrease with S (*P*=0.002)\                                         NR                          NR                                                   NR                                                           [@b79-ce-1-043]
                                                                                                                                                                                                                                      Ca or Al salts                    NSD with Ca or Al salts                                                                                                                                                                                            

  3                       Retrospective, n=583 (S), n=2923 (CaCO~3~), n=3664 (CaAc)                                                                                                                                                   Sevelamer\                        Lower with S vs Ca salts (*P*\<0.0001 S period vs Ca salts period)   S 46.9%\                    NR                                                   NR                                                           [@b85-ce-1-043]
                                                                                                                                                                                                                                      CaCO~3~\                                                                                               CaCO~3~ 42.4%\                                                                                                                                
                                                                                                                                                                                                                                      CaAc                                                                                                   CaAc 40.8%                                                                                                                                    

  3                       Retrospective, n=30 (S), n=25 (Ca salts)                                                                                                                                                                    Sevelamer\                        Lower with S vs Ca salts (*P*\<0.05)                                 S 77%\                      NR                                                   NR                                                           [@b25-ce-1-043]
                                                                                                                                                                                                                                      Ca salts                                                                                               Ca salts 36%\                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                             (*P*\<0.05 S vs Ca salts)                                                                                                                     

  3                       Switching study, 7 patients with high Ca × P product and severe hyperparathyroidism switched to S, 7 control patients with well-controlled Ca × P and mild hyperparathyroidism continued on calcium salts   Sevelamer\                        NSD vs baseline for S and Ca salts                                   NR                          S 7.37 (decline from 7.40 at baseline, *P*\<0.05)\   S 36 mmHg (decline from 42.5 mmHg at baseline, *P*\<0.05)\   [@b84-ce-1-043]
                                                                                                                                                                                                                                      Ca salts                                                                                                                           Ca salts NSD vs baseline                             Ca salts NSD vs baseline                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ca, calcium; CaAc, calcium acetate; CaCO~3~, calcium carbonate; NR, not reported; NSD, not statistically significantly different; RCT, randomized controlled trial; S, sevelamer.

###### 

Effects of sevelamer compared with calcium salts on occurrence of gastrointestinal adverse events

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Level of evidence**   **Design**                                                                                             **Treatment and mean dose**                                  **Outcome**                                                                        **Reference**
  ----------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------ ---------------------------------------------------------------------------------- -----------------
  2                       Open, 5 months, n=21 (S), n=21 (CaCO~3~)                                                               Sevelamer, initial dose 2.4 g/day increasing to 4.4 g/day\   Patients who discontinued due to digestive intolerance S 5/21 CaCO~3~ 0            [@b70-ce-1-043]
                                                                                                                                 CaCO~3~ 4.8 g/day                                                                                                                               

  2                       Double-blind, 8 weeks, n=50 (S), n=48 (CaAc)                                                           Sevelamer 6.9 g/day\                                         NSD S vs CaAc in subjective symptom score for gastrointestinal side effects        [@b65-ce-1-043]
                                                                                                                                 CaAc 7.1 g/day                                                                                                                                  

  2                       Open, 34 weeks, n=40 total                                                                             Sevelamer 4.09 g/day\                                        NSD S vs CaAc in occurrence of "constipation, diarrhea and other adverse events"   [@b40-ce-1-043]
                                                                                                                                 CaAc 3.9 g/day                                                                                                                                  

  2                       Open, 52 weeks, n=36 (S), n=46 (CaCO~3~)[a](#tfn22-ce-1-043){ref-type="table-fn"}\                     Sevelamer 5.9 g/day\                                         Gastrointestinal adverse events:\                                                  [@b10-ce-1-043]
                          Subanalysis of [@b21-ce-1-043], German and Austrian patients, with 11 additional patients randomized   CaCO~3~ 3.9 g/day                                            S 74%\                                                                             
                                                                                                                                                                                              CaCO~3~ 53%\                                                                       
                                                                                                                                                                                              (*P*=0.02 S vs CaCO~3~)\                                                           
                                                                                                                                                                                              Dyspepsia:\                                                                        
                                                                                                                                                                                              S 26%\                                                                             
                                                                                                                                                                                              CaCO~3~ 5%\                                                                        
                                                                                                                                                                                              (*P*\<0.01 S vs CaCO~3~)                                                           

  2                       Open, 52 weeks, n=108 randomized                                                                       Sevelamer 6.7 g/day\                                         NSD S vs CaAc in occurrence of gastrointestinal adverse events                     [@b22-ce-1-043]
                                                                                                                                 CaAc 4.6 g/day                                                                                                                                  

  3                       Open, crossover, 8 weeks for each treatment period, n=20                                               Sevelamer 5.2 g/day\                                         Occurrence of gastrointestinal complaints:\                                        [@b73-ce-1-043]
                                                                                                                                 CaCO~3~ 9 g/day                                              S 28%\                                                                             
                                                                                                                                                                                              CaCO~3~ 35%                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Number who completed the trial.

CaAc, calcium acetate; CaCO~3~, calcium carbonate; NSD, no statistically significant difference; S, sevelamer.
